Exosomes and prostate cancer management

Josson, 2014, miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer, Clin. Cancer Res., 20, 4636, 10.1158/1078-0432.CCR-14-0305 Josson, 2015, Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis, Oncogene, 34, 2690, 10.1038/onc.2014.212 Castellana, 2009, Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis, Cancer Res., 69, 785, 10.1158/0008-5472.CAN-08-1946 Zhao, 2016, Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism, Elife, 5, 10.7554/eLife.10250 Webber, 2010, Cancer exosomes trigger fibroblast to myofibroblast differentiation, Cancer Res., 70, 9621, 10.1158/0008-5472.CAN-10-1722 Webber, 2015, Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes, Oncogene, 34, 290, 10.1038/onc.2013.560 Ishii, 2011, Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells, J. Cell. Biochem., 112, 3604, 10.1002/jcb.23291 Ramteke, 2015, Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules, Mol. Carcinog., 54, 554, 10.1002/mc.22124 Chowdhury, 2015, Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts, Oncotarget, 6, 715, 10.18632/oncotarget.2711 Minciacchi, 2017, MYC mediates large oncosome-induced fibroblast reprogramming in prostate Cancer, Cancer Res., 77, 2306, 10.1158/0008-5472.CAN-16-2942 Morello, 2013, Large oncosomes mediate intercellular transfer of functional microRNA, Cell Cycle, 12, 3526, 10.4161/cc.26539 Bellezza, 2005, Extracellular matrix degrading enzymes at the prostasome surface, Prostate Cancer Prostatic Dis., 8, 344, 10.1038/sj.pcan.4500828 Kim, 2002, Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin, Cancer Res., 62, 6312 Lundholm, 2014, Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion, PLoS One, 9, 10.1371/journal.pone.0108925 Salimu, 2017, Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes, J. Extracell. Vesicles, 6, 10.1080/20013078.2017.1368823 Babiker, 2005, Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack, Prostate, 62, 105, 10.1002/pros.20102 Kim, 2014, Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment, Cancer Biol. Ther., 15, 409, 10.4161/cbt.27627 Poggio, 2019, Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory, Cell, 177, 414, 10.1016/j.cell.2019.02.016 Lu, 2018, Exosomal alphavbeta6 integrin is required for monocyte M2 polarization in prostate cancer, Matrix Biol., 70, 20, 10.1016/j.matbio.2018.03.009 Abd Elmageed, 2014, Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes, Stem Cells, 32, 983, 10.1002/stem.1619 Wang, 2015, Extracellular vesicle-mediated reversal of paclitaxel resistance in prostate cancer, Crit. Rev. Oncog., 20, 407, 10.1615/CritRevOncog.v20.i5-6.120 Hashimoto, 2018, Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A, Proc. Natl. Acad. Sci. U. S. A., 115, 2204, 10.1073/pnas.1717363115 Morhayim, 2015, Proteomic signatures of extracellular vesicles secreted by nonmineralizing and mineralizing human osteoblasts and stimulation of tumor cell growth, FASEB J., 29, 274, 10.1096/fj.14-261404 Itoh, 2012, Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation, J. Mol. Histol., 43, 509, 10.1007/s10735-012-9415-1 Karlsson, 2016, Tumor cell-derived exosomes from the prostate cancer cell line TRAMP-C1 impair osteoclast formation and differentiation, PLoS One, 11, 10.1371/journal.pone.0166284 Ye, 2017, Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer, Oncotarget, 8, 94834, 10.18632/oncotarget.22014 Probert, 2019, Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis, Oncogene, 38, 1751, 10.1038/s41388-018-0540-5 Li, 2019, Exosomes from LNCaP cells promote osteoblast activity through miR-375 transfer, Oncol. Lett., 17, 4463 Renzulli, 2010, Microvesicle induction of prostate specific gene expression in normal human bone marrow cells, J. Urol., 184, 2165, 10.1016/j.juro.2010.06.119 Panagopoulos, 2013, Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure, Mol. Cancer, 12, 118, 10.1186/1476-4598-12-118 Halin Bergstrom, 2016, Extracellular vesicles from metastatic rat prostate tumors prime the normal prostate tissue to facilitate tumor growth, Sci. Rep., 6, 31805, 10.1038/srep31805 Souza, 2018, Extracellular vesicles as drivers of epithelial-mesenchymal transition and carcinogenic characteristics in normal prostate cells, Mol. Carcinog., 57, 503, 10.1002/mc.22775 Hosseini-Beheshti, 2016, Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment, Oncotarget, 7, 14639, 10.18632/oncotarget.7052 Waugh, 2008, The interleukin-8 pathway in cancer, Cancer Res., 14, 6735 Singh, 2016, Exosome-mediated transfer of alphavbeta3 integrin from Tumorigenic to nontumorigenic cells promotes a migratory phenotype, Mol. Cancer Res., 14, 1136, 10.1158/1541-7786.MCR-16-0058 Fedele, 2015, The alphavbeta6 integrin is transferred intercellularly via exosomes, J. Biol. Chem., 290, 4545, 10.1074/jbc.C114.617662 Gaballa, 2020, Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchymal transition, Cancers (Basel), 12, 2300, 10.3390/cancers12082300 Read, 2017, Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles, Eur. J. Cancer, 70, 62, 10.1016/j.ejca.2016.10.017 Lin, 2017, Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes, Cancer Lett., 391, 74, 10.1016/j.canlet.2017.01.018 Bhagirath, 2019, BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2, Clin. Cancer Res., 25, 6532, 10.1158/1078-0432.CCR-19-0498 Lin, 2019, The paracrine induction of prostate cancer progression by caveolin-1, Cell Death Dis., 10, 834, 10.1038/s41419-019-2066-3 Corcoran, 2014, miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression, Prostate, 74, 1320, 10.1002/pros.22848 Kharaziha, 2015, Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel, Oncotarget, 6, 21740, 10.18632/oncotarget.3226 Cao, 2019, Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate cancer chemoresistance through p53, Biochem. Biophys. Res. Commun., 515, 345, 10.1016/j.bbrc.2019.05.120 Li, 2016, Exosome-derived microRNAs contribute to prostate cancer chemoresistance, Int. J. Oncol., 49, 838, 10.3892/ijo.2016.3560 Kawakami, 2015, Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance, Int. J. Oncol., 47, 384, 10.3892/ijo.2015.3011 Kato, 2020, CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients, Heliyon, 6, 10.1016/j.heliyon.2020.e04138 Kato, 2015, Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer, Urol. Oncol., 33, 385, 10.1016/j.urolonc.2015.04.019 Lorenc, 2020, Exosomes in prostate cancer diagnosis, prognosis and therapy, Int. J. Mol. Sci., 21, 10.3390/ijms21062118 Saber, 2020, Exosomes are the driving force in preparing the soil for the metastatic seeds: lessons from the prostate cancer, Cells, 9, 10.3390/cells9030564 Tai, 2020, The role of extracellular vesicles in prostate cancer with clinical applications, Endocr. Relat. Cancer, 27, R133, 10.1530/ERC-20-0021 Vlaeminck-Guillem, 2015, When prostate cancer circulates in the bloodstream, Diagnostics Basel (Basel), 5, 428, 10.3390/diagnostics5040428 Vlaeminck-Guillem, 2018, Extracellular vesicles in prostate cancer carcinogenesis, diagnosis, and management, Front. Oncol., 8, 222, 10.3389/fonc.2018.00222 Salciccia, 2021, Biomarkers in prostate cancer diagnosis: from current knowledge to the role of metabolomics and exosomes, Int. J. Mol. Sci., 22, 4367, 10.3390/ijms22094367 Hatano, 2021, Extracellular vesicles in prostate cancer: a narrative review, Transl. Androl. Urol., 10, 1890, 10.21037/tau-20-1210 Akoto, 2021, Role of exosomes in prostate cancer metastasis, Int. J. Mol. Sci., 22, 3528, 10.3390/ijms22073528 Catalona, 2018, Prostate cancer screening, Med. Clin. North Am., 102, 199, 10.1016/j.mcna.2017.11.001 Matoso, 2019, Defining clinically significant prostate cancer on the basis of pathological findings, Histopathology, 74, 135, 10.1111/his.13712 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur. Urol., 79, 243, 10.1016/j.eururo.2020.09.042 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer, Eur. Urol., 79, 263, 10.1016/j.eururo.2020.09.046 Aurilio, 2020, Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications, Cells, 9, 10.3390/cells9122653 Nilsson, 2009, Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer, Br. J. Cancer, 100, 1603, 10.1038/sj.bjc.6605058 Ronquist, 2012, Prostasomes are mediators of intercellular communication: from basic research to clinical implications, J. Intern. Med., 271, 400, 10.1111/j.1365-2796.2011.02487.x Duijvesz, 2015, Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer, Int. J. Cancer, 137, 2869, 10.1002/ijc.29664 Mitchell, 2009, Can urinary exosomes act as treatment response markers in prostate cancer?, J. Transl. Med., 7, 4, 10.1186/1479-5876-7-4 Biggs, 2016, Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry, Oncotarget, 7, 8839, 10.18632/oncotarget.6983 Lance, 2011, Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer, Expert Rev. Anticancer Ther., 11, 1341, 10.1586/era.11.134 Logozzi, 2017, Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients, Cancer Lett., 403, 318, 10.1016/j.canlet.2017.06.036 Mizutani, 2014, Isolation of prostate cancer-related exosomes, Anticancer Res., 34, 3419 Park, 2019, Author correction: prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer, Sci. Rep., 9, 6051, 10.1038/s41598-019-41385-w Tavoosidana, 2011, Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer, Proc. Natl. Acad. Sci. U. S. A., 108, 8809, 10.1073/pnas.1019330108 Turay, 2016, Proteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients, Cancer Invest., 34, 1, 10.3109/07357907.2015.1081921 Pan, 2017, Exosomes in diagnosis and therapy of prostate cancer, Oncotarget, 8, 97693, 10.18632/oncotarget.18532 Wang, 2020, Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer, Crit. Rev. Oncol. Hematol., 145, 10.1016/j.critrevonc.2019.102860 Park, 2016, Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer, Sci. Rep., 6, 30386, 10.1038/srep30386 Bryzgunova, 2016, Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients, PLoS One, 11, 10.1371/journal.pone.0157566 Donovan, 2015, A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result, Prostate Cancer Prostatic Dis., 18, 370, 10.1038/pcan.2015.40 McKiernan, 2018, A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/ml at initial biopsy, Eur. Urol., 74, 731, 10.1016/j.eururo.2018.08.019 McKiernan, 2016, A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy, JAMA Oncol., 2, 882, 10.1001/jamaoncol.2016.0097 McKiernan, 2020, A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy, BMC Urol., 20, 138, 10.1186/s12894-020-00712-4 Tutrone, 2020, Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL, Prostate Cancer Prostatic Dis., 23, 607, 10.1038/s41391-020-0237-z Visser, 2020, Commercialized blood-, urinary- and tissue-based biomarker tests for prostate cancer diagnosis and prognosis, Cancers (Basel), 12, 3790, 10.3390/cancers12123790 Cheng, 2014, SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene, PLoS Genet., 10, 10.1371/journal.pgen.1004656 de la Calle, 2021, Clinical utility of 4Kscore(®), exosomeDx™ and magnetic resonance imaging for the early detection of high grade prostate cancer, J. Urol., 205, 452, 10.1097/JU.0000000000001361 Chen, 2021, Molecular origin, expression regulation, and biological function of androgen receptor splicing variant 7 in prostate cancer, Urol. Int., 105, 337, 10.1159/000510124 Vlaeminck-Guillem, 2020, Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer, Transl. Androl. Urol., 9, 2483, 10.21037/tau-20-968 Miyake, 2018, Comparison of alternative androgen receptor-axis-targeted agent (ARATA) and docetaxel as second-line therapy for patients with metastatic castration-resistant prostate Cancer With progression after initial ARATA in real-world clinical practice in Japan, Clin. Genitourin. Cancer, 16, 219, 10.1016/j.clgc.2017.11.007 Matsubara, 2017, Clin. Genitourin. Cancer, 15, e1073, 10.1016/j.clgc.2017.07.016 Oh, 2018, Urol. Oncol., 36, 500 e1, 10.1016/j.urolonc.2018.08.002 Oh, 2017, Clin. Genitourin. Cancer, S1558-7673, 30170 Sonpavde, 2018, Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer, BJU Int., 121, 871, 10.1111/bju.14152 George, 2020, Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States, Clin. Genitourin. Cancer, S1558-7673, 30392 Markowski, 2017, Clinical utility of CLIA-Grade AR-V7 testing in patients with metastatic castration-resistant prostate cancer, JCO Precis Oncol, 2017, 1 Graf, 2020, Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer, Eur. Urol., 77, 170, 10.1016/j.eururo.2019.08.020 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N. Engl. J. Med., 371, 1028, 10.1056/NEJMoa1315815 Zhang, 2020, Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate Cancer, Clin. Genitourin. Cancer, 18, 1, 10.1016/j.clgc.2019.09.015 Wang, 2020, Prognostic value of androgen receptor splice variant 7 in the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis, Front. Oncol., 10 Markowski, 2016, Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide, Prostate, 76, 1484, 10.1002/pros.23232 Armstrong, 2019, Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study, J. Clin. Oncol., 37, 1120, 10.1200/JCO.18.01731 Scher, 2018, Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer, JAMA Oncol., 4, 1179, 10.1001/jamaoncol.2018.1621 Scher, 2017, Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer, Eur. Urol., 71, 874, 10.1016/j.eururo.2016.11.024 Maillet, 2019, Improved androgen receptor splice variant 7 detection using a highly sensitive assay to predict resistance to abiraterone or enzalutamide in metastatic prostate cancer patients, Eur Urol Oncol, S2588-9311 Lu, 2020, Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer, J Circ Biomark, 9, 13, 10.33393/jcb.2020.2163 Del Re, 2017, The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients, Eur. Urol., 71, 680, 10.1016/j.eururo.2016.08.012 Del Re, 2021, Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide, Prostate Cancer Prostatic Dis., 24, 524, 10.1038/s41391-020-00309-w Del Re, 2019, AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer, BJU Int., 124, 693, 10.1111/bju.14792 Joncas, 2019, Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients, Prostate, 79, 1767, 10.1002/pros.23901 Nimir, 2019, Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes, Cells, 8, 688, 10.3390/cells8070688 Strati, 2019, Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer, Analyst, 144, 6671, 10.1039/C9AN00999J Foroni, 2020, When less is more: specific capture and analysis of tumor exosomes in plasma increases the sensitivity of liquid biopsy for comprehensive detection of multiple androgen receptor phenotypes in advanced prostate cancer patients, Biomedicines, 8, 131, 10.3390/biomedicines8050131 Woo, 2019, Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer, Lab Chip, 19, 87, 10.1039/C8LC01185K Yin, 2017, Androgen receptor variants mediate DNA repair after prostate cancer irradiation, Cancer Res., 77, 4745, 10.1158/0008-5472.CAN-17-0164 Yu, 2018, Nano-vesicles are a potential tool to monitor therapeutic efficacy of carbon ion radiotherapy in prostate cancer, J. Biomed. Nanotechnol., 14, 168, 10.1166/jbn.2018.2503 Gaur, 2015, Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy, Oncotarget, 6, 29161, 10.18632/oncotarget.4971 Li, 2019, Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer, Front. Pharmacol., 10, 1436, 10.3389/fphar.2019.01436 Li, 2019, Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy, APL Bioeng, 3, 10.1063/1.5087122 Saari, 2015, Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells, J. Control. Release, 220, 727, 10.1016/j.jconrel.2015.09.031 Handy, 2018, Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions, Future Oncol., 14, 907, 10.2217/fon-2017-0531 Thery, 2009, Membrane vesicles as conveyors of immune responses, Nat. Rev. Immunol., 9, 581, 10.1038/nri2567 Cho, 2005, Exosomes: a new delivery system for tumor antigens in cancer immunotherapy, Int. J. Cancer, 114, 613, 10.1002/ijc.20757 Reimers, 2019, Immunotherapy in metastatic castration-resistant prostate cancer: past and future strategies for optimization, Curr. Urol. Rep., 20, 64, 10.1007/s11934-019-0931-3 Rountree, 2011, Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy, Cancer Res., 71, 5235, 10.1158/0008-5472.CAN-10-4076 Shi, 2020, Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer, Prostate, 80, 811, 10.1002/pros.23996 Kosgodage, 2017, Chloramidine/bisindolylmaleimide-I-mediated inhibition of exosome and microvesicle release and enhanced efficacy of cancer chemotherapy, Int. J. Mol. Sci., 18, 1007, 10.3390/ijms18051007 Datta, 2017, Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells, Cancer Lett., 408, 73, 10.1016/j.canlet.2017.08.020 Datta, 2018, High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: a drug repurposing strategy for advanced cancer, Sci. Rep., 8, 8161, 10.1038/s41598-018-26411-7